B-lymphoblastic leukemia/lymphoma: Overexpression of nuclear DNA repair protein PARP-1 correlates with antiapoptotic protein Bcl-2 and complex chromosomal abnormalities

Human Pathology

Volumn 45, Issue 8, 2014, Pages 1582-1587

  Pournazari, Payam ^a   Padmore, Ruth F ^b   Kosari, Farid ^a   Scalia, Peter ^b   Shahbani Rad, Meer Taher ^a   Shariff, Sami ^a   Demetrick, Douglas J ^a   Bosch, Mark ^a   Mansoor, Adnan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

B lymphoblastic leukemia lymphoma; Bcl 2; Chromosomal abnormalities; PARP 1; Prognosis

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANEUPLOIDY; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DIPLOIDY; DNA REPAIR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SEX RATIO;

B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA; BCL-2; CHROMOSOMAL ABNORMALITIES; PARP-1; PROGNOSIS;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; YOUNG ADULT;

EID: 84904616095     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.11.024     Document Type: Article

References (34)

1. N. Gökbuget, and D. Hoelzer Treatment of adult acute lymphoblastic leukemia Semin Hematol 46 2009 64 75
2. StatBite Five-year survival rates among children with acute lymphoblastic leukemia J Natl Cancer Inst 101 2009 703
3. C.J. Harrison, and L. Foroni Cytogenetics and molecular genetics of acute lymphoblastic leukemia Rev Clin Exp Hematol 6 2002 91 113
4. M.J. Borowitz, M. Devidas, and S.P. Hunger et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood 111 2008 5477 5485
5. T.M. Harned, and P. Gaynon Relapsed acute lymphoblastic leukemia: current status and future opportunities Curr Oncol Rep 10 2008 453 458
6. A. Prokop, T. Wieder, and I. Sturm et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo Leukemia 14 2000 1606 1613
7. C.H. Pui, and W.E. Evans Treatment of acute lymphoblastic leukemia N Engl J Med 354 2006 166 178
8. S.H. Swerdlow, E. Campo, N.L. Harris, and E.S. Jaffe B-lymphoblastic leukemia/lymphoma S.H. Swerdlow, E. Campo, N.L. Harris, World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008 IARC Press Lyon 168 179
9. J.M. Rowe, and A.H. Goldstone How I treat acute lymphocytic leukemia in adults Blood 110 2007 2268 2275
10. E.U. Kurz, and S.P. Lees-Miller DNA damage-induced activation of ATM and ATM-dependent signaling pathways DNA Repair 3 2004 889 900
11. T. Stankovic, M. Hubank, and D. Cronin et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses Blood 103 2004 291 300
12. R.T. Bree, C. Neary, A. Samali, and N.F. Lowndes The switch from survival responses to apoptosis after chromosomal breaks DNA Repair 3 2004 989 995
13. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 2008 3785 3790
14. W.G. Kaelin Jr. The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 2005 689 698
15. M. Schweiger, B. Auer, and H.J. Burtscher et al. The Fritz-Lipmann lecture. DNA repair in human cells: biochemistry of the hereditary diseases Fanconi's anaemia and Cockayne syndrome Eur J Biochem 165 1987 235 242
16. S.A. Andrabi, N.S. Kim, and S.W. Yu et al. Poly(ADP-ribose) (PAR) polymer is a death signal Proc Natl Acad Sci U S A 103 2006 18308 18313
17. S. Kannan, W. Fang, and G. Song et al. Notch/HES1-mediated PARP-1 activation: a cell type-specific mechanism for tumor suppression Blood 117 2011 2891 2900
18. E. Marston, V. Weston, and J. Jesson et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response Blood 113 2009 117 126
19. G.S. Salomons, H.J. Brady, and M. Verwijs-Janssen et al. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia Int J Cancer 71 1997 959 965
20. A. Bettaieb, L. Dubrez-Daloz, and S. Launay et al. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells Curr Med Chem Anticancer Agents 3 2003 307 318
21. C. Dutta, T. Day, and N. Kopp et al. Bcl-2 suppresses PARP-1 function and nonapoptotic cell death Cancer Res 72 2012 4193 4203
22. C. Laulier, and B.S. Lopez The secret life of Bcl-2: apoptosis- independent inhibition of DNA repair by Bcl-2 family members Mutat Res 751 2012 247 257
23. H. Goulding, S. Pinder, and P. Cannon et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples Hum Pathol 26 1995 291 294
24. V. Ossovskaya, I.C. Koo, E.P. Kaldjian, C. Alvares, and B.M. Sherman Upregulation of poly (ADP-ribose) polymerase-1 (PARP-1) in triple-negative breast cancer and other primary human tumor types Genes Cancer 1 2010 812 821
25. W. Min, U. Cortes, Z. Herceg, W.M. Tong, and Z.Q. Wang Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis Carcinogenesis 31 2010 2058 2065
26. J. Ménissier de Murcia, M. Ricoul, and L. Tartier et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse EMBO J 22 2003 2255 2263
27. S.W. Yu, S.A. Andrabi, and H. Wang et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death Proc Natl Acad Sci U S A 103 2006 18314 18319
28. R.M. Golla, M. Li, and Y. Shen et al. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks Hematol Oncol 30 2012 4175 4179
29. A. Tutt, M. Robson, and J.E. Garber et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
30. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R.A. Sharma DNA repair pathways as targets for cancer therapy Nat Rev Cancer 8 2008 193 204
31. M. Tsapis, M. Lieb, and F. Manzo et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway Int J Biochem Cell Biol 39 2007 1500 1509
32. C. Visco, A. Tzankov, and Z.Y. Xu-Monette et al. Patients with diffuse large B-cell lymphoma of germinal center origin with Bcl-2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBcl rituximab-CHOP Consortium Program study Haematologica 98 2013 255 263
33. T.S. Kumar, V. Kari, and B. Choudhary et al. Anti-apoptotic protein Bcl-2 down-regulates DNA end joining in cancer cells J Biol Chem 285 2010 32657 32670
34. S.X. Yang, S. Kummar, and S.M. Steinberg et al. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas Cancer Biol Ther 8 2009 2004 2009